Neoplasms

Digestive System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Paclitaxel

Apatinib

Albumin-Bound Paclitaxel

Cisplatin

Tubulin Modulators

Antimitotic Agents

Carilizumab was administered every 2 weeks. The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped.

Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.

Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.

carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)

JUN ZHOU, MD

LIN SHEN, MD

This trial will explore the efficacy and safety of camrelizumab combined with apatinib mesylate and radiotherapy and chemotherapy (paclitaxel (albumin binding) combined with gemcitabine and cisplatin) in the treatment of locally advanced pancreatic cancer in patients with locally advanced pancreatic cancer.

This trial is a prospective, observational, single-center, single-arm clinical research.Conversion treatment lasted for a total of 12 weeks, with one treatment cycle every two weeks.Carilizumab was administered every 2 weeks.

The patients were orally taken apatinib after meals and evaluated by DLT(3+3) in the first 2 cycles.The drugs were stopped for 2 weeks after the start of radiotherapy.Before radiotherapy, patients received 2 cycles of karyolizumab combined with apartinib and chemotherapy. Radiotherapy was performed in the first week of cycle 3 with a total dose of 30Gy in five doses within one week.Imaging evaluation was conducted once every 6 weeks. If the patients met the indications for surgical resection, the treatment was stopped

The Transformation of Locally Advanced Pancreatic Cancer.

Carrilizumab Combined With Apatinib Mesylate and Radiotherapy and Chemotherapy for the Transformation of Locally Advanced Pancreatic Cancer.

The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit.

The date of first treatment until the date of progression using the RECIST 1.1 criteria, or death due to any cause, whichever comes first.

Number of patients meeting the resectability criteria of NCCN 2020 V1

Number of patients meeting the R0 resection standard.

Number of patients meeting the R1 resection standard.

Number of Adverse Events using NCI CTCAE 5.0

Spots Global Cancer Trial Database for carrilizumab；apatinib mesylate；locally progressive pancreatic cancer